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Abstract 
Background: Epigenome-wide association studies (EWAS) based on human brain samples allow a deep and direct 
understanding of epigenetic dysregulation in Alzheimer’s disease (AD). However, strong variation of cell-type propor-
tions across brain tissue samples represents a significant source of data noise. Here, we report the first EWAS based on 
sorted neuronal and non-neuronal (mostly glia) nuclei from postmortem human brain tissues.
Results: We show that cell sorting strongly enhances the robust detection of disease-related DNA methylation 
changes even in a relatively small cohort. We identify numerous genes with cell-type-specific methylation signatures 
and document differential methylation dynamics associated with aging specifically in neurons such as CLU, SYNJ2 and 
NCOR2 or in glia RAI1,CXXC5 and INPP5A. Further, we found neuron or glia-specific associations with AD Braak stage 
progression at genes such as MCF2L, ANK1, MAP2, LRRC8B, STK32C and S100B. A comparison of our study with previous 
tissue-based EWAS validates multiple AD-associated DNA methylation signals and additionally specifies their origin 
to neuron, e.g., HOXA3 or glia (ANK1). In a meta-analysis, we reveal two novel previously unrecognized methylation 
changes at the key AD risk genes APP and ADAM17.
Conclusions: Our data highlight the complex interplay between disease, age and cell-type-specific methylation 
changes in AD risk genes thus offering new perspectives for the validation and interpretation of large EWAS results.
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Background
Alzheimer’s disease (AD) is a fatal neurodegenera-
tive disorder and the most common form of age-related 
dementia. The majority of AD cases are diagnosed as 
late-onset AD but its aetiology is thought to start much 
earlier in life and to slowly progress until first symptoms 
emerge  [53]. At the cellular level, AD can be character-
ized by the appearance and extent of (i) extracellular 
plaques from accumulations of insoluble amyloid beta 
filaments, (ii) intracellular neurofibrillary tangles of 
hyperphosphorylated tau  [25, 115, 117] and (iii) neu-
roinflammation. According to the amyloid cascade 
hypothesis  [39], AD results from neurotoxic amyloid 
beta plaques which form from excess of APP protein fila-
ments derived by sequential proteolytic cleavage by β - or 
γ-secretases [15, 103]. Neuropathologically, AD is classi-
fied according to spread of disease marks across the brain 
regions (Braak stages)  [13]. Despite intense research, 
molecular causes for AD and the relationship to normal 
aging are not well understood. Only a minority of AD 
cases can be explained by mutations in the genes APP, 
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PSEN1 and PSEN2 [16, 22]. Recently, several studies sug-
gest neuroepigenetic mechanisms to be involved in AD 
etiology suggesting that the sum of acquired epigenetic 
alterations over lifespan could play a role [68, 88, 89]. In 
the central nervous system (CNS), these processes are 
indispensable for cells to execute complex functions such 
as learning and memory, but are also involved in the con-
text of aging and neuropathologic processes  [2, 10, 23, 
116]. To date, DNA methylation at cytosines (5-mC) in 
a CpG sequence context is the best understood and most 
extensively studied epigenetic mark [75, 76] which can be 
target for further modifications from 5-mC to 5-hydroxy-
methylcytosine, to 5-formylcytosine to 5-carboxymethyl-
cytosine by the family of Tet enzymes [124]. In particular, 
5-hmC the most prominent oxidized form of cytosine 
methylation is identified in cells of the CNS  [64] and 
recent studies in the brain reported altered proportions 
upon aging and in disease [5, 19, 26, 43, 63, 70, 98, 136].
Two recent large EWAS based on human brain tissue 
reported Braak stage-associated methylation changes at 
several genes such as ANK1,RPL13, CDH23, HOXA3 and 
BIN1  [27, 82]. Notably, methylation changes at the APP 
gene locus have so far only been shown for individual AD 
cases  [52, 129, 137] while a larger study could not con-
firm this observation [6]. One main obstacle is that in the 
cortex cell-type composition changes upon aging and/
or disease progression  [122]. This heterogeneity in tis-
sue composition constitutes a major source of noise in 
epigenetic profiles and compromises a clean distinction 
of age, cell-type and disease-related changes across sam-
ples. Several bioinformatic approaches were developed 
to address this problem [47, 48, 97, 104]. However, there 
is an ongoing dispute concerning their proper usabil-
ity [105, 144]. In our study, we circumvent this problem 
by profiling cells separated into neuronal- and glia frac-
tions of cortices from 31 healthy donors and AD patients 
with well-defined Braak stages. A comparison of cell sort-
ing and bulk tissue-based screens reveals that cell-type 
purification efficiently reduces confounding noise gener-
ated by variable cell composition and enhances the detec-
tion of disease-related changes. Therefore, we detect a 
substantial number of Braak stage-associated markers 
previously only found in much larger datasets of total 
brain tissue. In addition, cell sorting allows assignment of 
identified signals to cell-type origin and reveals that next 
to neurons also glia cells experience strong epigenetic 
alterations upon AD progression.
Results
Cellular heterogeneity in brain tissue undermines 
the association analysis for Braak stage
The aim of this study is to address DNA methylation 
changes in the human brain that are associated with 
aging and/or with increasing Braak stages. Before start-
ing our cell sorting approach, we performed an initial 
DNA methylation screen on unsorted 128 postmortem 
bulk brain samples (63 frontal (FC) and 65 temporal 
cortex (TC) samples) derived from 52 healthy controls 
(CTRL) and 76 AD donors (Additional file 2: Tables S1–
S2) using Illumina’s HumanMethylation 450k bead array 
platform. Following state of the art data processing  [72] 
(see "Methods" section), we obtained data for more than 
460,000 CpGs per sample. To calculate the association 
between DNA methylation and Braak stage progression 
or aging, we applied multiple linear regression models 
thereby correcting for sex, age and batch effects (see prin-
cipal component analysis; Additional file  1: Fig.  S1k, l). 
In addition, we calculated for each sample the neuronal 
content following the method described by Houseman 
et al. [47]. We separately analyzed FC and TC samples to 
exclude brain region effects (Additional file 1: Fig. S1a–d) 
(Additional file 2: Tables S3–S6). With respect to aging, 
we identified only six differentially methylated CpGs 
(DMCGs) overlapping between FC and TC when com-
paring the two top 1000 ranked CpGs (Additional file 1: 
Fig. S1g) while 171 were common among the top 1000 
Braak stage-associated CpG  sets (Additional file  1: Fig. 
S1h). Also, only little overlap was observed for aging and 
Braak-DMCGs within FC or TC (Additional file  1: Fig. 
S1e, f ). We used the top 1000 top ranking Braak-DMCGs 
in a cluster analysis, but the samples did not clearly dif-
ferentiate for diagnosis (Additional file  1: Fig. S1i) and 
the observed changes were between low and high Braak 
stages were mostly low (Additional file  1: Fig.  S1j) sug-
gesting a limited discriminative power of the analysis. In 
addition, none of our 200 top ranking CpGs from FC or 
TC showed overlap with a recently published large AD-
EWAS also based on brain tissue material [82]. A possible 
explanation for this could be that our cohort was smaller 
compared to the published EWAS. Alternatively, we rea-
soned that 5-mC profiles might strongly differ between 
populations (cohorts) or show variable grades of hetero-
geneity in individual cell-type composition. To overcome 
this problem, we decided to proceed with a reduced 
number of samples for which we physically separated 
neuronal and non-neuronal cell-types.
Cell separation identifies a broad range of cell‑type‑specific 
methylation signatures
We performed NeuN immunolabeling followed by FACS 
separation  [3, 51, 55, 80, 93, 100, 128] to obtain neu-
ronal (NeuN-positive, referred to as neurons) and non-
neuronal nuclei (NeuN-negative, referred to as glia) 
from 31 human postmortem occipital cortex samples. 
From this, we generated 62 epigenome-wide cell-type-
specific profiles (Additional file  2: Tables S1–S2) on an 
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Illumina 450k methylation array platform (for general 
work flow, processing and quality checks see "Methods" 
section and Fig.  1a). Cluster analysis revealed a clear 
overall separation of neuronal and glia samples (Fig. 1b). 
To systematically define cell-type-specific methylation 
sites (ct-DMCGs), we compared neuron and glia sam-
ples (controls only) by a two-sided t test and filtered for 
autosomal CpGs with a significant p value (Bonferroni 
corrected) and methylation difference of at least 20% 
(Fig.  1c, Additional file  2: Table  S7). In total, we identi-
fied 57,908 ct-DMCGs (approx. 12% of all sites) distrib-
uted across 11,279 genes, many of which are known to 
be differentially expressed in neurons and glia cells such 
as SYNPO  [96] (cg06732545, p = 7.09 ∗ 10−29 , rank 82), 
FOXP1  [125] (cg21836903, p = 4.48 ∗ 10−27 , rank 329) 
and MBP   [38] (cg24446429, p = 3.28 ∗ 10−22 ). A bit 
more than half (54%) of all ct-DMCGs were hypermeth-
ylated in neurons (Fig. 1d). Most of the ct-DMCGs were 
located at gene body and promoter regions and only very 
few in intergenic regions (Fig. 1d). Compared to the array 
design, we observed more hypomethylated ct-DMCGs at 
the gene body while hypermethylated ct-DMCGs were 
enriched at gene promoters and exon 1 regions (Fig. 1e). 
A GO enrichment analysis revealed mostly neurologi-
cal process such as ‘neuron projection morphogenesis’, 
‘modulation of synaptic transmission’ and ‘regulation 
of neurotransmitter levels’ (Additional file  2: Table  S8). 
We also validated a larger set of differential loci using 
deep bisulfite amplicon sequencing (Fig.  1f ). We found 
a high concordance between 450k array data and NGS 
data ( R2 = 0.912; Additional file  1: Fig.  S2b, Additional 
file  2: Table  S9). In line with previous findings  [75], we 
detected pronounced non-CpG methylation levels mostly 
at CpA dyads for neurons and to much a lesser extent for 
glia (Fig. 1f ). In addition, we validated cell-type-specific 
expression at the protein level using immunohistochemi-
cal staining with specific antibodies against SORL1 and 
FOXP1, respectively (Additional file  1: Fig. S2c, Addi-
tional file  2: Table  S10). Taken together we confirm a 
successful and clear separation of neuronal and glia cell 
fractions from fresh frozen brain tissue.
We next compared our results to a recent study 
that also applied NeuN-based separation of human neu-
ron and glia cells   [35]. From this dataset, we selected 
all 23 healthy Caucasian samples (Additional file  2: 
Table  S2). The correlation between our and the Guinti-
vano et al. study was very good ( R2 > 0.99) both for the 
neuronal and glia methylation profiles (Fig. 1g, Additional 
file 1: Fig. S2d). Moreover, the majority of neuron to glia 
differences were highly similar (Additional file 1: Fig. S2e) 
as clearly demonstrated by the concordant placement in a 
principal component analysis (Additional file 1: Fig. S2a). 
About 48,220 (88.3%) ct-DMCGs overlapped with those 
identified in our own data (Fig.  1h). We would like so 
stress that the Guintivano cohort was derived from fron-
tal cortex while our samples were from occipital cortex. 
So we wondered if NeuN-sorted samples from different 
brain regions might exhibit distinct methylation signa-
tures. To follow this question we performed a correlation 
analysis on a subset of healthy control samples from our 
cohort (occipital cortex) and from the Guintivano study 
that are matched for sex, age and cell-type (n = 5). Nota-
bly, we observe the same very high degree of correlation 
within and across cohorts (Additional file 2: Table S11), 
indicating that NeuN-sorted methylation profiles from 
both regions are comparable. Further, in a PCA analy-
sis, they clustered together independent of cohort (data 
not shown). Given this high agreement, we conclude that 
NeuN-based cell separation from human cortical post-
mortem samples is a robust and reproducible approach, 
even across brain regions and cohorts. We therefore felt 
confident to include the 23 samples from the Guintivano 
study as additional controls in our subsequent analyses. 
Other samples from this study including non-Caucasian 
controls were not used.
Neuron and glia methylomes change distinctly upon aging
To analyze age-associated DNA methylation changes 
in both cell fractions (Table  1)  we applied multiple lin-
ear regression models separately for the neuron and glia 
samples correcting for the confounding variables sex and 
technical batch effects (see "Methods" section). While we 
(See figure on next page.)
Fig. 1 Experimental setup and cell-type-specific DNA methylation signatures. a General work flow scheme for neuron and glia cell-type 
separation and DNA methylation profiling. b Cluster analysis on complete data shows full separation of neuron and glia samples. c Volcano plot 
for identification of 57,908 cell-type-specific CpGs (ct-DMCGs, dark red) in sorted CTRLs. d Genomic distribution of ct-DMCGs that are hypo- or 
hypermethylated in neurons. CpGs are classified in respect of hypo-or hypermethylation in neurons compared to glia. e Relative distribution of 
ct-DMCGs in relation to array design. f NGS-based validation for exemplary ct-DMCGs in a subset of neuron and glia samples. Columns represent 
methylation levels of cytosines at CpGs (upper panels) or CpAs (lower panels). Rows are samples ordered by similarity. Black triangles mark CpGs 
that are present on the 450k array. NC/GC: neuron/glia controls, N3-N6/G3-G6: neuron/glia Braak stages III–VI. g Similarity of neuronal methylation 
profiles (CTRLs only) for our own study (dataset 1) and data from Guintivano et al [35] (dataset 2). h Overlap of ct-DMCGs as defined by datasets 1 
and 2, respectively
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detected many aging-DMCGs with large methylation dif-
ferences between young and old individuals (Fig.  2a, c; 
Additional file 1: Fig. S2a) there was only a minor overlap 
( n = 49 ) of the top 1000 aging-DMCGs between neurons 
and glia (Fig. 2b), indicating distinct methylation dynam-
ics for both cell-types upon aging (Additional file  2: 
Tables S12, S13). Most aging-DMCGs were found in gene 
body, promoter and first exon regions while intergenic 
regions were underrepresented (Fig.  2d, e). For both 
cell-types, we predominantly observe a hypomethylation 
with increasing age (Fig.  2d, Additional file  1: Fig.  S3). 
For several genes in the top 1000 lists, we observed 
prominent age-associated changes in neurons such as 
FAM53B (10 hits), CLU (8) and NCOR2 (6) (Additional 
file  2: Table  S14). All the three genes encode proteins 
important for neuronal processes   [36, 54, 60]. Interest-
ingly, the aging-DMCGs at the CLU gene are specifically 
concentrated in the first intron (Fig.  2f ) at a previously 
described alternative promoter where a specific CLU iso-
form is initiated from [11, 74]. These CpGs show a strong 
loss of DNA methylation with increasing age in neurons 
(Additional file  1: Fig.  S4). The effect is independent of 
AD as we observe this in healthy controls and AD sam-
ples to the same extent. In nuclei from glia, we confirmed 
aging-DMCGs at loci which were previously described as 
aging markers in peripheral blood such as ELOVL2 and 
FHL2  [59]. In addition, we identified a set of new genes 
with clustered and prominent aging-DMCGs glia such as 
RAI1 (6 hits), CUX1, DIP2C, FLJ45983 and ITPK1 (all 5) 
(Additional file 2: Table S14). For both neurons and glia, 
the top ten aging-associated KEGG pathways featured 
ErbB signaling pathway, Neuroactive ligand-receptor 
interaction and MAPK signaling pathway (Additional 
file  2: Table  S19). Notably, we found numerous aging-
DMCGs with asymmetric or even opposing methylation 
dynamics in neurons and glia, respectively (Fig. 2g, Addi-
tional file 1: Fig. S5). Such cases nicely illustrate the com-
plexity of aging across cell-types and the advantage of cell 
sorting over bulk tissue.
Among genes with multiple age-dynamic ct-DMCGs 
(Additional file 2: Table S15) we identify prominent can-
didates with negative cell-type-specific aging dynamics 
Table 1 Top 25 aging-DMCGs identified in the meta-analysis
Rank P value 
(meta‑
analysis)
P value (neuron) P value (glia) TargetID Chr Position Gene Region FDR
1 4.34E−27 6.58E−09 1.00E−20 cg13327545 10 22623548 2.0763E−21
2 9.38E−26 5.55E−10 2.69E−18 cg16867657 6 11044877 ELOVL2 TSS1500 2.2438E−20
3 2.53E−25 8.99E−09 4.56E−19 cg20224218 9 129261375 FAM125B Body 4.0346E−20
4 4.38E−25 5.03E−06 1.42E−21 cg10804656 10 22623460 5.2387E−20
5 6.46E−25 9.09E−14 1.17E−13 cg14919554 5 43018629 6.1811E−20
6 8.12E−25 2.95E−17 4.54E−10 cg02426178 19 10747142 SLC44A2 Body 6.4746E−20
7 1.65E−24 5.49E−16 5.01E−11 cg03984866 4 8161776 ABLIM2 TSS1500 1.0465E−19
8 1.75E−24 1.52E−09 1.92E−17 cg10906284 12 63544430 AVPR1A 1stExon 1.0465E−19
9 2.38E−24 2.13E−06 1.88E−20 cg17117277 19 3822126 ZFR2 Body 1.2651E−19
10 5.41E−24 2.75E−08 3.36E−18 cg06022942 10 8095484 FLJ45983 TSS200 2.5882E−19
11 7.95E−24 3.53E−14 3.86E−12 ch.6.1693624F 6 83767401 UBE2CBP Body 3.4576E−19
12 1.32E−23 5.62E−09 4.06E−17 cg24954207 3 128217091 5.2626E−19
13 1.77E−23 4.00E−09 7.68E−17 cg08234504 5 139013317 6.5138E−19
14 1.92E−23 8.17E−11 4.10E−15 cg02492920 7 150659969 KCNH2 Body 6.5384E−19
15 2.05E−23 1.01E−11 3.53E−14 cg14299508 8 105907690 6.5384E−19
16 3.75E−23 2.50E−12 2.64E−13 cg08594681 8 27468684 CLU 1stExon 1.1213E−18
17 4.63E−23 6.45E−14 1.27E−11 cg08342886 6 33240066 VPS52 TSS1500 1.303E−18
18 1.20E−22 9.22E−10 2.34E−15 cg00303378 1 159825552 VSIG8 Body 3.0971E−18
19 1.23E−22 1.21E−10 1.83E−14 cg23813012 1 14026482 PRDM2 TSS1500 3.0971E−18
20 1.38E−22 5.01E−10 4.98E−15 ch.13.22912778R 13 24014778 3.2806E−18
21 1.44E−22 1.20E−08 2.17E−16 cg06639320 2 106015739 FHL2 TSS200 3.2806E−18
22 1.77E−22 1.31E−09 2.45E−15 cg15393490 1 207996459 3.8491E−18
23 1.90E−22 6.33E−08 5.46E−17 cg26880525 1 209877941 HSD11B1 5UTR 3.8672E−18
24 1.94E−22 6.83E−13 5.17E−12 cg04211309 16 58056296 3.8672E−18
25 2.33E−22 5.12E−15 8.29E−10 cg09131339 1 109914235 SORT1 Body 4.4588E−18
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(i.e., neuron-glia differences are decreased in old individ-
uals compared to young ones) such as C21orf34 (6 hits), 
ANK1 (5), PTPRN2 (5), HDAC4 (5), but also APP (2).
ANK1 was recently reported as a top differentially 
methylated marker associated with Braak stage pro-
gression in two large EWAS  [27, 82]. Indeed we find 
that the two top ANK1 CpGs and several others 
reported in these studies exhibit strong and complex 
cell-type dynamics overage (Additional file  1: Fig.  S6). 
Increased cell-type-specific aging dynamics were also 
seen in DIP2C5 (5) and PAX6 (5). The latter encodes 
an transcription factor that is important in the devel-
opment processes of neural tissues and has been impli-
cated in healthy aging and AD [81].
Next, we independently validated our top aging-
DMCGs using another public cohort of NeuN-sorted 
prefrontal cortex brain samples  [61]. From this dataset 
(GSE98203), we only used healthy, NeuN-positive con-
trols as NeuN-negative data was not available. For our 
top 50 neuronal aging-DMCGs we found highly similar 
methylation dynamics overage in these samples (exam-
ples see Additional file  1: Fig.  S7) illustrating that our 
approach is valid. These findings may have profound 
implications for the interpretation of epigenetic effects 
in age-related diseases. In many studies, bioinformatic 
methods are used to adjust tissue samples for cell com-
position effects  [46–48, 104] which is inferred from ref-
erence datasets. In the light of our observations, this 
procedure could be problematic if the used references 
and tissue samples have a different age distribution 
because the tool potentially selects discriminative mark-
ers that have diverse aging dynamics. Indeed, our in sil-
ico estimations of neuronal content in brain tissue show 
systematic differences depending on the usage of a ref-
erence set of young age or of old age (Additional file  1: 
Fig. S8a, b). In addition to that we find high variation of 
neuronal content across all studies and tissues analyzed 
(Additional file 1: Fig. S8c). Our analysis emphasizes that 
cell-type-specific methylation dynamics upon aging are 
prominent and have to be considered as complex con-
founding factors in epigenetic studies of brain tissues.
Both neurons and glia show Braak stage‑associated 
methylation changes
We then focused on the association of DNA methyla-
tion with Braak stage progression in neurons and glia 
cells, respectively (Fig. 3a, b, Table 2). Similar to the pre-
vious analysis we analyzed neuron and glia separately 
and applied regression models that used the samples’ 
individual Braak score as a factor. In addition, we cor-
rected for potential confounding variables (aging, sex 
and batch effects). Again, we observe reduced overlap 
between the top 1000 Braak-DMCGs of both cell-types 
(Fig.  3c) indicating that neuronal and glia cells respond 
differentially during AD progression. For numerous 
Braak-DMCGs we could observe unbalanced or even 
reciprocal methylation dynamics in neurons and glia 
upon Braak stage progression (Additional file 1: Fig. S9). 
These diametric methylation changes in the two major 
cell-types of the brain could not be detected in bulk brain 
tissue screens but rather be interpret as changes in cell 
proportions. Similarly, the overlap between top Braak-
DMCGs and aging-DMCGs is small (Fig. 3d, e), suggest-
ing differential methylation dynamics for aging and Braak 
stages. Approx. 60% of DMCGs become hypomethylated 
with increasing Braak stages (Additional file 1: Fig. S10). 
They are mostly located in gene body, promoters and 
first exon regions (Fig. 3f ) while intergenic regions were 
largely underrepresented (Fig. 3g). Absolute methylation 
differences for the top 1000 Braak-DMCGs remained 
small but clearly higher than the overall changes seen in 
tissue-based analyses (Fig. 3h, Additional file 1: Fig. S1j). 
The top ranked neuronal Braak-DMCGS are located 
at genes involved in cortical neurotransmitter trans-
port. For example, the top-ranking CpG, “cg02746913” 
( pvalue : 1.23 ∗ 10−07 ; Additional file  2: Table  S16) is 
located proximal to the gene SEC14L1  [108]. The top 3 
ranking site, “cg06549928” ( pvalue : 1.15 ∗ 10−06 , Fig. 4c, 
Additional file  2: Table  S16) is located at the LRRC8B 
locus  [87]. In addition, we identify clusters of DMCGs 
in genes such as MCF2L (7 hits), FAM83H (6), ARSG (3) 
and HOXA3 (3) (Additional file 2: Table S14).
The glial top marker “cg06549928” 
( pvalue : 3.83 ∗ 10−9 ; Additional file 2: Table S17) in the 
gene LRRC8B was also found to be prominent in our 
neuron analysis. Clustered glia DMCGs were associated 
with DIP2C (6 hits), HLA-DPB1 (6), GNG7 (5) and HOPX 
(5) (Additional file  2: Table  S14). GNG7 encodes for a 
calcium-dependent G coupled receptor that is coupled to 
dopamine receptors and its expression level in astrocytes 
becomes upregulated upon inflammatory stimuli [24, 37, 
112, 114]. In our list of top glial DMCGs we further iden-
tify two hits in the ANK1 gene (Additional file 2: Tables 
S14, S17) recently reported as the top marker in two large 
AD screens on bulk tissue [27, 82]. Our data suggest that 
the reported epigenetic changes in ANK1 are restricted 
to glia.
Meta‑analysis for Braak stage progression detects robust 
methylation changes in HOXA3, APP and ANK1
Next, we reasoned that a combination of the cell-type-
specific results from the neuron and glia analyses should 
reflect the combined epigenetic burden in the CNS upon 
Braak stage progression. The combined meta-analy-
sis was performed using Fisher’s Method and results 
were ranked according to p values (Fig. 4a, Table 2). As 
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Table 2 Top 10 Braak stage DMCGs plus 25 selected CpGs from 200 top entries
Rank P value 
(meta‑
analysis)
P value (neuron) P value (glia) TargetID Chr Position Gene Region Probe SNPs FDR
1 1.50E−13 1.15E−06 3.83E−09 cg06549928 1 89990868 LRRC8B 5UTR 7.17624E−08
2 6.43E−11 4.64E−06 4.98E−07 cg21913630 7 128828599 SMO TSS200 1.53811E−05
3 2.05E−10 3.04E−05 2.54E−07 cg16562251 1 166845621 TADA1 1stExon 3.26918E−05
4 2.90E−10 1.15E−05 9.63E−07 cg08738571 12 32655192 FGD4 1stExon rs56168193 3.45416E−05
5 3.61E−10 9.00E−06 1.54E−06 cg22140756 2 177895827 3.45416E−05
6 4.81E−10 7.42E−06 2.52E−06 cg04913265 11 133939627 JAM3 Body 3.8353E−05
7 8.78E−10 1.69E−05 2.07E−06 cg20693608 4 113152836 AP1AR TSS200 6.0007E−05
8 1.57E−09 7.82E−06 8.20E−06 cg24449302 15 66679100 MAP2K1 TSS200 rs77540803 7.02674E−05
9 1.60E−09 7.69E−06 8.51E−06 cg13172549 7 27153636 HOXA3 5UTR 7.02674E−05
10 1.61E−09 2.63E−06 2.50E−05 cg04547723 14 75421960 PGF 5UTR 7.02674E−05
11 1.67E−09 1.49E−05 4.58E−06 cg07835289 1 236030215 LYST 5UTR 7.02674E−05
15 2.27E−09 0.00021772 4.33E−07 cg11817993 14 92572978 ATXN3 TSS200 7.02674E−05
21 5.19E−09 3.14E−05 7.12E−06 cg02037503 14 23540729 ACIN1 1stExon 0.000118237
27 1.04E−08 7.43E−05 6.24E−06 cg03040740 13 99084682 FARP1 Body rs6491426 0.000184279
32 1.44E−08 0.00087784 7.40E−07 cg13859639 11 2846716 KCNQ1 Body 0.000215287
38 2.41E−08 0.00041341 2.70E−06 cg03907612 6 41703314 TFEB 5UTR 0.000303416
39 2.60E−08 7.11E−05 1.70E−05 cg16568373 17 4853368 ENO3 TSS1500 0.000318944
48 3.48E−08 2.84E−05 5.76E−05 cg05884192 14 52515736 NID2 Body rs2516585 0.000334891
53 3.75E−08 0.00012506 1.42E−05 cg08883485 1 201619787 NAV1 Body 0.000334891
58 4.55E−08 4.14E−05 5.24E−05 cg23712970 14 23540735 ACIN1 1stExon 0.000374624
74 6.71E−08 1.05E−05 0.0003106 cg08843538 2 210288784 MAP2 1stExon 0.000429299
76 6.94E−08 4.79E−05 7.07E−05 cg04542489 14 23775746 BCL2L2 TSS1500 0.00043306
102 1.24E−07 4.82E−05 0.00012891 cg06355720 1 153333350 S100A9 3UTR rs743566 0.000581604
103 1.27E−07 5.37E−05 0.00011905 cg26327118 6 39693366 KIF6 TSS200 0.000589892
104 1.31E−07 1.08E−05 0.00061189 cg16258854 2 20648194 RHOB 1stExon rs1062292 0.000595763
111 1.41E−07 0.00052315 1.36E−05 cg08866780 21 27543523 APP TSS1500 0.000604315
112 1.42E−07 0.01466411 4.90E−07 cg03613822 17 7115140 DLG4 Body 0.000604315
126 1.71E−07 5.41E−06 0.00161641 cg06291595 14 74960292 NPC2 TSS1500 0.000646609
131 1.86E−07 0.01071281 8.90E−07 cg04153489 8 41655983 ANK1 TSS1500 0.000679278
133 1.99E−07 2.07E−05 0.00049571 cg19447671 2 176032513 ATF2 5UTR 0.000715825
134 2.04E−07 0.00058734 1.79E−05 cg10313337 16 68823690 CDH1 Body 0.000728335
141 2.18E−07 0.00020684 5.47E−05 cg01015899 12 120663812 PXN 5UTR 0.000737839
152 2.41E−07 2.45E−05 0.00051347 cg27212541 3 49507385 DAG1 TSS200 0.00075801
161 2.68E−07 0.00027187 5.17E−05 cg07745886 8 42150794 IKBKB Body 0.000796369
199 4.19E−07 0.00095868 2.35E−05 cg01231165 2 9695142 ADAM17 Body 0.001001966
Fig. 2 Aging analysis in neurons and glia. a Genomic p value distribution for the aging analysis in neurons. The arrow marks a region on 
chromosome 8 with a concentrated set of top-ranking CpGs (see f). b Overlap of top 1000 aging-DMCGs between neuron and glia, but approx. 25% 
of each set are ct-DMCGs. c Methylation change from 8 youngest to 8 oldest samples for top 1000 aging CpGs in neurons and glia, respectively. 
Boxes colored as in d. d Genomic region classification of top 1000 aging-DMCGs from neuron and glia, respectively. CpGs are classified in respect of 
hypo- or hypermethylation in 8 oldest versus 8 youngest CTRL samples. e Relative distribution of top 1000 aging-DMCGs in relation to array design. 
f p-value distribution at the clusterin gene locus (CLU) in the age analysis in neuron (green) and glia (red), respectively. A set of 10 adjacent CpGs 
(dashed square) shows strong age-association in healthy neurons (but only partially in glia). Numbers on x-axis give coordinates on chromosome 
8 (hg19). Cartoon below illustrates the relative location of exons (black boxes), promoters (black triangles) and annotated sites of high DNaseI 
hypersensitivity (gray boxes) according to UCSC genome browser. g Age-dependent methylation changes that occur exclusively in one cell-type 
can lead to either emergence (left panel) or disappearance (mid) of significant differences between cell-types. Aging effects that are synchronized 
between cell-types are stable ct-DMCGs over lifetime (right). Adding AD samples leads to similar results (bright dashed lines: regression lines based 
on CTRLs, dark dashed lines: CTRLs + AD cases) (color figure online)
(See figure on next page.)
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a plausibility check for our approach, we performed a 
cluster analysis of the 200 top-ranking combined Braak-
DMCGs using all samples. The clustering shows an 
almost perfect cell-type-specific split on the first level 
but on the second or third split disease-related sub-
clusters (Fig.  4b). In our top 200 list (Additional file  2: 
Tables S14, S18) the most covered KEGG pathways 
were ‘MAPK signaling’, ‘neurotrophin signaling’ and 
‘Alzheimer’s disease’ (Additional file  2: Table  S19). We 
identified multiple hits for the HOXA3 gene with a high 
significance for four CpGs (‘cg13172549’, ‘cg07061298’, 
‘cg00921266’, ‘cg22962123’; ranks: 10, 44, 91 and 158). 
All four CpGs show a solid hypermethylation upon 
Braak stage progression with more pronounced changes 
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in glia (Fig.  4c, Additional file  1: Fig.  S5). Two of these 
four DMCGs HOXA3 were recently reported in a large 
EWAS screen by Lunnon et al [27, 82] analyzing several 
hundred samples. To systematically examine the overlap 
between our top 200 markers with all published large 
tissue-based EWAS studies we retrieved the methyla-
tion data from publicly available tissue-based AD data-
sets (GSE59685, GSE80970). Together with our own 
Fig. 3 Braak stage analysis in neuron and glia. a Genomic p value distribution for the Braak stage progression analysis in neurons. b Genomic p 
value distribution for the Braak stage progression analysis in glia. c Overlap for the top 1000 ranking Braak-DMCGs from neuron and glia. d Overlap 
of top 1000 Braak-DMCGs and top 1000 aging-DMCGs from neuron, 10% of Braak-DMCGs are ct-DMCGs. e Same as d but for glia top DMCGs. 
Compared to neuron there are more ct-DMCGs among top Braak-DMCGs in glia. f Distribution across genomic regions of top 1000 Braak-DMCGs 
from neuron and glia. CpGs were classified as hypo- or hypermethylated in respect to methylation change from 8 youngest CTRLs to 8 oldest 
Braak stage VI samples. Most methylation changes are at gene body, promoters and 1st exon regions. g Similar to f but in relation to array design. h 
Methylation changes from 8 youngest CTRLs to 8 oldest Braak stage VI samples for top 1000 Braak-DMCGs in neurons and glia, respectively. Boxes 
colored as in f  (color figure online)
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dataset this meta-analysis comprised about 700 samples 
from three brain regions (frontal, temporal, occipital and 
entorhinal cortex). Following a uniform data processing, 
we calculated absolute methylation changes between 
low, middle and high Braak stages for the individual top 
CpGs (Fig.  4d). We compared the changes associated 
with Braak progression for our top Braak-DMCGs (top 
200 neuron, top 200 glia, top 200 combined analysis) and 
the top 100 lists from tissue-based EWAS (Fig. 4d). This 
confirmed two of the four HOXA3 gene markers across 
all studies and a remarkable overlap for many more 
previously reported DMCGs (Fig.  4d, Additional file  1: 
Fig. S8). For the majority of these DMCGs methylation 
changes were more pronounced in sorted cells than in 
bulk samples (Additional file 1: Fig. S12) and interestingly 
often found in glial cells (e.g., ANK1). Notably, among the 
novel Braak-DMCGs in our top 200 DMCGs we found a 
marker near the APP gene (cg08866780, p = 1.41 ∗ 10−7 , 
rank 111, Fig. 4c, Additional file 2: Table S18) one of the 
most relevant AD genes  [39, 115]. The DMCG is located 
in the APP promoter and becomes hypomethylated dur-
ing Braak stage progression in neurons and in glia but 
starting from different basal levels (Fig. 3c). This CpG did 
not show significant changes upon aging in controls only 
(neuron: P = 0.4 , glia: p = 0.46 ) and the effect remained 
when only individuals older than 64 years were consid-
ered (Additional file  1: Fig.  S11a) suggesting an age-
independent methylation change at the APP promoter 
linked to Braak stage. Methylation changes for APP were 
not detected in our bulk brain tissue samples (Additional 
file  1: Fig.  S11b) nor reported in the top 100 lists from 
tissue screens [27, 82] indicating a gain of sensitivity for 
pre-sorted samples.
Discussion
Our first systematic cell-type-specific DNA methyla-
tion screen on a cohort of postmortem cortex samples 
shows that cell sorting strongly enhances the detection 
of DNA methylation markers and allows a deep insight 
into cell-type-specific dynamics in the context of aging 
and AD Braak stage progression, respectively. In general, 
we observe a deep interplay between DNA methylation 
changes associated with aging, with cell-type and with 
disease progression. Many CpGs reveal distinct meth-
ylation dynamics during aging in neurons and glia, 
respectively. This suggests that the biological “clock” of 
neuronal and glial cells show characteristic epigenetic 
signatures in the brain. Nevertheless, we also found CpGs 
with ‘synchronized’ dynamics across the two cell-types 
(such as in the pan-aging marker ELOVL2). In the con-
text of a highly age-related and complex disease such as 
AD, it is of great value to better understand epigenetic 
effects linked to aging as it supports the interpretation 
of molecular changes. Starting off with a conventional 
tissue-based screen of unsorted cortical tissues from 
a representative cohort of 128 well diagnosed healthy 
donors and AD patients we realized that this approach 
comes with a low detection power and consequently a 
minimal number of epigenetic markers which moreover 
mostly do not overlap with other large EWAS studies. To 
overcome this obstacle we developed a sorting protocol 
for neuronal and glial nuclei fractions and performed 
two simultaneous 450K analyses per donor. In line with 
recently published data  [35], we find tens of thousands 
robust methylation changes between the neuronal and 
glial fractions. This strong overlap and the high similar-
ity of samples (age- and sex-matched) between the two 
studies illustrate the high reproducibility of the cell sort-
ing approach. By using linear regression models we then 
identified robust cell-type-specific DNA methylation dif-
ferences associated with either aging or Braak stage pro-
gression (or both). While age-associated changes have 
been reported previously on mixed tissues [58, 118] our 
study highlights the presence of cell-specific age-related 
methylation dynamics in human primary cells such as 
neuron and glia. This finding is well compatible with 
findings reported by others [122] who found age-specific 
transcriptional differences between neuron and glial cells 
in the human brain. As one prominent example, we iden-
tify a cell-type-specific cluster of age-associated DMCGs 
located in an alternative promoter of the clusterin CLU, 
a well-known AD risk gene  [8, 30, 40, 67, 69, 94, 94, 110, 
138, 141, 143, 145]. At this promoter, neurons become 
increasingly hypomethylated over lifetime—while 
Fig. 4 Meta-analysis and integration of external brain tissue data. a Manhattan plot for the Braak stage meta-analysis. Selected CpGs located at 
the genes LRRC8B, HOXA3 and APP are marked by arrows. b Cluster analysis for the 200 top-ranking Braak-DMCGs. c Methylation change over Braak 
stages for exemplary top CpGs at the genes HOX3A (top), LRRC8B (middle) and APP (bottom). Box colored as in b. d Methylation change between 
Braak stages for various CpG sets based on our own data (Study 1: our sorted and tissue samples) or on external tissue data (Study 2: GSE59685 [82]; 
Study 3: GSE80970 [121]). Rows are organized as sets of CpGs derived from our own 200 top-ranking results (neuron, glia, meta-analysis), the top 
100’s from Lunnon and partners (FC, TC, EC, CER) and 100 randomly selected sites. Dashed squares indicate the dataset initially used to identify the 
corresponding CpG set. ‘Cross study’ depicts two CpGs at the HOXA3 locus co-identified in our screen and in Study 2. Note that for most CpGs the 
methylation difference across Braak stages are strongest in sorted samples even when the CpG set was originally identified in tissues. (FC: frontal 
cortex, TC: temporal cortex, EC: entorhinal cortex)  (color figure online)
(See figure on next page.)
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changes in glia are only moderate or absent. This effect 
is independent of AD diagnosis indicating that the epi-
genetic changes in CLU are a sign of “natural aging” con-
tributing to disease aetiology. In the human two distinct 
CLU isoforms have recently been described with oppos-
ing functions in cell survival and apoptosis  [21, 28, 73, 
130, 131]. Our data indicate that an alternative promoter 
becomes epigenetically “activated” in aged neurons and 
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the expression of a pro-apoptotic CLU isoform may con-
tribute to degeneration predominantly in the CNS. Our 
observation that over lifetime cell-type-specific DMCGs 
can emerge or vanish indicates that besides cell compo-
sition age represents a complex confounding parameter 
in tissues based EWAS. Our studies show that such phe-
nomena require strong attention particularly when using 
cell-type-specific data as references for calculation of 
cell-type proportions and adjustments. We believe that 
our analysis combined with data from Guintivano et  al. 
represents a valid resource to appropriately identify and 
interpret age-related effects for data deconvolution. 
Moreover, we were able to replicate our top neuronal 
aging-DMCGs in an independent dataset which nicely 
illustrates that our findings are reproducible. The main 
goal of our study was to identify DMCGs associated with 
Braak stage progression on a cell-type-specific basis. In 
line with earlier studies, we detected DMCGs in several 
genes involved in neurotransmitter homeostasis and 
transport such as SEC14L1, MCF2L and LRRC8B  [41, 
87, 108]. In AD, neurotransmitter systems are largely 
disturbed  [32, 90] and it is known that ACh-releasing 
neurons are explicitly vulnerable to amyloid beta 1–42 
exposition and predominantly lost upon Braak stage pro-
gression [4, 99, 113]. In line with this interpretation, we 
find epigenetic changes in three genes. MCF2L encodes 
a protein involved in the Mcf2l-RhoA-ROCK signaling 
pathway that mediates Il1rapl1-dependent formation 
and stabilization of glutamatergic synapses of cortical 
neurons  [41]. SEC14L1 encodes a protein involved in 
vesicular trafficking of acetylcholine (ACh) to synaptic 
vesicles [108]. The LRRC8 genes encode for anion chan-
nels that transport the neurotransmitters glutamate, 
aspartate and gamma-aminobutyric acid (GABA) and the 
LRRC8B protein has been reported to modulate the sub-
strate specificity of the channels  [87]. Most intriguingly 
the very prominent changes for LRRC8B in both neu-
ronal and glial cells indicate that this anion channel gene 
plays a multiple role in the AD pathology. Among the 
many DMCGs changing in glial cells upon Braak stage 
progression, we found two prominent CpGs in the ANK1 
gene, a gene recently reported as a top candidate in 
two large EWAS based on hundreds of bulk tissue sam-
ples [27, 82]. Our finding underlines that these top mark-
ers predominantly change in glia cells. Indeed, a recent 
study using laser microdissection reported increased 
ANK1 expression in AD microglia but not in neurons or 
astrocytes  [92]. To evaluate the neuronal and glial “epi-
genetic burden” in the AD brain upon Braak stage pro-
gression we performed a meta-analysis combining the 
data of significant “clean”, i.e., cell separated, DMCGs 
from glia and neuron. This combined analysis validates 
a series of concurrent changes in known AD genes such 
as APP, HOXA3 and ADAM17 and confirms potentially 
new AD loci such as LRRC8B and MCF2L. The detec-
tion of a Braak stage-associated epigenetic change in 
the APP gene is of particular importance. To our knowl-
edge, we report the first systematic analysis confirm-
ing a few unlinked single case reports  [52, 129, 137] for 
APP. This DMCG is located at the promoter overlap-
ping with a confirmed CTCF binding region (Additional 
file 1: Fig. S11c). This region has been shown to regulate 
APP transcription [133, 134, 142]. Our data suggest that 
during AD progressive loss of DNA methylation at this 
region results in enhanced binding of CTCF thus increas-
ing APP transcription. Our analysis further identifies six 
CpGs high ranking Braak-DMCGs at the HOXA3 gene. 
Several of them were previously reported by recent large 
EWAS studies   [27, 82, 121]. With the help of cell sort-
ing, we could detect these signals in a much smaller 
cohort illustrating the gain of sensitivity after separation 
of major cell-types. The HoxA gene cluster is known to 
coordinate neuronal development, organization of neu-
ral circuits and regulation of postmitotic neurons   [79, 
91, 101,135] and abnormal expression or epigenetic dys-
regulation of Hox genes has been reported for several 
neurological diseases such as Huntington’s disease, Par-
kinson’s disease, C9ORF72-related dementias and glio-
blastoma [31, 45, 65, 66, 78, 139].
There are several limitations to our work. We used 
classic bisulfite conversion chemistry in our study that is 
known to be masked for 5-mC and 5-hmC. Future work 
could employ methods, such as oxidative or Tet-assisted 
bisulfite conversion to elaborate alterations of individual 
methylation forms. Further, for AD an predominant loss 
of pyramidal neurons has been reported [12]. Therefore, 
some of our results might reflect a shift in neuronal sub-
type proportions. Additional sorting of neuronal and 
glial fractions into subpopulations such as dopaminer-
gic, glutamatergic and GABAergic neurons or glial sub-
types (astrocytes, oligodendrocytes and microglia) could 
further enhance the sensitivity of such screens like ours. 
Indeed combined FACS separation with NeuN and SOX6 
has been shown to effectively separate glutamatergic and 
GABAergic neurons in mouse and identified clear addi-
tional neuronal epigenetic differences  [62]. However, to 
date, only these two markers are available and have not 
been successfully used for postmortem human tissues 
probes. An alternative approach to dissect the nature of 
heterogeneity by single nuclei analyses. Such promising 
approaches have recently been applied on single NeuN-
positive nuclei in mouse and human  [84], but are still 
not in a robust state for large-scale comparative stud-
ies on challenging postmortem material. Moreover, we 
included combined nuclei sorted from occipital cortex 
and frontal cortex in our study to increase sample size. 
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While in brain tissue-based screens strong methylation 
differences across brain regions have been shown  [26, 
43], this was so far not observed in sorted NeuN-negative 
(glia) nuclei  [109]. For NeuN-positive samples limited 
methylation changes were found only between certain 
regions  [109]. Further studies are required to systemati-
cally dissect neuronal methylation differences across and 
within specific brain regions, especially in the cortex. 
However, in our Braak association analysis, we do not 
see an enrichment of cell-type markers exclusively found 
in frontal cortex or in occipital cortex (Additional file 2: 
Table S21).
Conclusions
We demonstrate the application of our approach requires 
a relatively small cohort to robustly identify new and 
assign known disease-associated epigenetic signals to 
specific cell populations. We conclude that sorting for 
major cell-types enables systematic EWAS with less sam-
ples compared to common tissue-based screens reducing 
time, costs and labor. Taken together, our study high-
lights cell-type composition and aging as major con-
founding factors in complex tissue analyses and strongly 
recommends to conduct EWAS on pre-sorted cell-types.
Methods
Human brain tissue samples and neuropathological 
classification of AD
For our study, we used snap-frozen human postmortem 
cortical tissue from 159 individuals that donated their 
brains for research (Additional file  2: Tables S1, S2). 
For 128 frontal and temporal cortex samples, we used 
the bulk tissue while for the 31 occipital cortex sam-
ples (Brodmann Area 17–19) we isolated neuronal and 
glial nuclei populations. Samples were provided by the 
Neurobiobank Munich (NBM) and are well character-
ized by age, gender, disease history and neuropathologi-
cal findings including Braak stage measurements in the 
analyzed subregions. All cases were collected according 
to the NBM standard protocols established by the Brain-
Net Europe and BrainNet Germany. Written informed 
consent was obtained according to the guidelines of 
the local ethics committee. Besides samples stored at 
−80 ◦C for molecular analysis some parts of the brains 
were formalin-fixed and paraffin-embedded (FFPE) for 
detailed anatomical and neuropathological evaluations: 
According to the NBM standards, up to 25 different brain 
regions were analyzed and neuropathological reports 
were drawn in accordance with the National Institute on 
Aging-Alzheimer’s Association guidelines for the neu-
ropathologic assessment of Alzheimer’s disease [50], the 
guidelines for the staging of Alzheimer disease-associ-
ated neurofibrillary pathology using paraffin sections and 
immunocytochemistry by Braak et  al. [13], the CERAD 
(Consortium to Establish a Registry for Alzheimer’s 
Disease) guidelines  [95] and the phases of amyloid beta 
deposits in the human brain by Tahl et al. [126]. Donors 
with any indications for bleedings, infarctions, stroke, 
tumors or sepsis were not considered for this study.
Separation of neuronal and glia nuclei
Human postmortem occipital cortex (Brodmann area 
17–19) neuronal and glia nuclei were separated by flu-
orescence-assisted isolation of immunolabeled nuclei 
using a NeuN- (RBFOX3-) specific antibody as described 
elsewhere  [75, 93]. Thereby, most neuronal cell-types 
throughout the nervous system show positivity for 
NeuN, only distinct neuronal cell-types such as cerebel-
lar Purkinje cells, olfactory bulb mitral cells and retinal 
photoreceptor cells stain negative  [128]. Briefly, 600 mg 
of cortex tissue was accurately dissected, cut into small 
pieces after removing of leptomeninx and dissolved in 11 
ml tissue lysis buffer (TLB) (10 mM Tris-HCl (pH 8), 0.1 
mM EDTA, 3 mM Mg(Ac)2 , 5 mM CaCl2 , 1 tablet pro-
teinase inhibitor cocktail, 0.1 mM PMFS, 0.16 mM DTT, 
0.1% Igepal, 0.32 M sucrose). After homogenization by 
douncing, samples were transferred into ultracentrifu-
gation tubes. Carefully 20 ml of nuclei separation buffer 
(NSB) (10 mM Tris-HCl (pH 8), 3 mM Mg(Ac)2 , 1 tab-
let proteinase inhibitor cocktail, 0.1 mM PMFS, 0.16 mM 
DTT, 1.8 M sucrose) were pipetted onto the bottom of 
the tubes. Separation of nuclei was performed using a 
Hitachi Sorvall Discovery 90SE ultracentrifuge with a 
Sorvall TH-641 rotator (Sorvall, Breda, Netherlands) at 
24,400 rpm (1 h, 4 ◦C ). Nuclei pellets were resuspended 
in 4 ml ice-cold nuclei protection buffer (NPB) (2.7 mM 
KCl, 137 mM NaCl, 1.8 mM KH2PO4, 10 mM Na2HPO4 , 
1 tablet proteinase inhibitor cocktail) and incubated on 
ice for 20 min. Neuronal nuclei were labeled by incuba-
tion for 1 h at RT with 6 µ l mouse-anti-NeuN-antibody 
(1  mg/ml) (Millipore, Eschborn, Germany) followed by 
addition of 6 µ l fluorescence-labeled secondary antibody 
(Alexa Fluor 546 goat-anti-mouse (2 mg/ml), Invitrogen, 
Darmstadt, Germany), 3 µ l DAPI (4’,6-Diamidin-2-phe-
nylindol, Roth, Karlsruhe, Germany) and another incuba-
tion for 1 h in the dark. After centrifugation (8000 rpm, 
30  s) pellets were resuspended in 3  ml ice-cold PBS 
and used for flow-cytometrical separation of neuronal 
(NeuN+ / DAPI+) and glial nuclei (NeuN−/DAPI+) on 
a FACSAria II device (BD Biosciences, Frankin Lakes, 
USA). Purity of nuclear fractions was > 98% as checked 
by re-FACS and high-throughput fluorescence micros-
copy (IN Cell Analyzer 2000, GE Healthcare, Chalfont St. 
Giles, UK).
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Infinium 450k bead chip methylation profiling and data 
analysis
DNA extraction was performed using the QIAamp DNA 
Micro Kit (Qiagen, Hilden, Germany) according to the 
manufacturer’s protocol. DNA was dissolved in 90 µ l 
nuclease-free water and centrifuged at 14,000 rpm for 1 
min. DNA was stored at −80 ◦C for further use. Bisulfite 
treatment was performed using 1 µ g of genomic DNA in 
the EZ DNA Gold Methylation Kit (Zymo, Irvine, USA) 
according to manufacturer’s protocol, except that the 
final elution volume was 12 µ l. To assess DNA meth-
ylation signatures of 485,512 CpGs, we used Infinium 
HumanMethylation450 BeadChips (Illumina, San Diego, 
USA) according to the manufacturer‘s protocol. Arrays 
were scanned on an Illumina HiScan device.
Data analysis
For methylation data processing and analysis we essen-
tially followed recent guidelines on 450k data analy-
sis [72]. Briefly, we performed quantile normalization and 
background subtraction using the R package minfi  [1] 
and batch effect correction with Combat  [57] from the 
sva package  [71]. Methylation calls were generated as 
beta values, ranging from 0 to 1, representing 0% and 
100% methylation, respectively. We removed probes with 
a detection p value > 0.01 in any samples. All samples 
had a probe call rate > 99% and showed very high cor-
relations ( R2 = 0.99 ) within cell-types (Additional file 1: 
Fig.  S13). Data from the study of Guintivano et  al.  [35] 
were downloaded from NCBI GEO database (GSE41826; 
only the 23 healthy Caucasian controls were used) and 
processed the same way as our own data. Two additional 
external brain tissue datasets (GSE59685 and GSE80970) 
were downloaded and used for detailed comparisons. 
Data was downloaded as processed beta values (dasen 
normalized, no background subtraction) and corrected 
for batch effects with Combat. For the cell-type-specific 
analyses on aging or Braak stage progression, we merged 
our sorted dataset with data from Guintivano and col-
leagues to obtain a combined dataset of 478,416 CpGs 
and 108 sorted samples (78 controls and 30 AD samples). 
Then we run a principal component analysis (Additional 
file  1: Fig.  S2) and correlated the principal components 
(PC) to known variables. PC1 showed best correlation 
with array batches ( p = 2.86 ∗ 10−13 ), PC2 with cell-
type ( p = 8.8 ∗ 10−97 ), PC3 with sex ( p = 4.29 ∗ 10−43 ) 
and PC4 with age ( p = 1.08 ∗ 10−17 ). We applied multi-
ple linear regression models to find associations of DNA 
methylation and Braak stages with correction for con-
founding factors age and sex. We also corrected for tech-
nical batch effects in our model by including principal 
components 1 (PC1) from a principal component analy-
sis as it shows high correlation to array batches :
Since epigenomes are highly cell-type-specific we run 
this model separately for neuronal and glia samples. Then 
we performed a meta-analysis to combine results from 
the primary analyses using Fisher’s method with:
Power analyses are difficult for EWAS as numerous 
markers have shown high correlations  [72] and estab-
lished methods to correct for multiple testings are likely 
to be too stringent. Therefore, if not noted otherwise we 
worked with nominal p values as done in other recent 
EWAS  [27, 82]. Nevertheless, we additionally provide 
FDR adjusted p values in all relevant result tables. GO 
enrichment analyses were performed with the GOril la 
tool using gene symbols according to Illumina annota-
tion. KEGG pathway analyses were performed by con-
verting relevant CpG identifiers to associated entrez-IDs 
according to Illumina annotation. Then, we used the R 
Package Pathview  [85] for mapping to KEGG pathways. 
For comparative analyses we grouped samples into three 
groups with low (Braak stages 0, I, II; average age: 48.3), 
medium (III, IV; 85) or high (V, VI; 77.9) Braak staging.
Estimation of neuronal cell proportions in brain tissue data
For the estimation of neuronal proportions in tissue data, 
we used the Houseman et al. surrogate measures of cell 
mixtures approach. As reference markers, we used the 
top-ranking 600 CpGs from the comparison (Student’s t 
test) of neuron and glia healthy control samples. Cell pro-
portions were then calculated for each tissue sample with 
the ‘projectCellType’ function from the minfi R-software 
package.
Immunohistochemical staining
Immunohistochemical staining to assess AD classifica-
tion was performed by investigation of up to 25 differ-
ent brain regions according to the NBM protocols and 
formalin-fixed and paraffin-embedded. Thereby the 
extent of neurofibrillary tangle pathology was assessed by 
immunohistochemical staining of hyperphosphorylated 
tau (AT8) according to the guidelines published by Braak 
et al. and classified to stage 0 to VI [13]. Additionally, we 
performed stainings for DAPI, SORL1 and FOXP1 of 
occipital cortex regions (BA 17-19). Pictures were made 
using an Olympus BX50 microscope and a 20× objective 
(Olympus, Tokyo, Japan) as well as a Color View III cam-
era (Soft Imaging System, Münster, Germany). We quan-
tified signals from several representative cases where 
(1)
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FFPE-tissue of target region was available (three pictures 
for each sample, Additional file  2: Table  S3). Statistical 
evaluation was done using ANOVA and Newman-Keuls 
post hoc test.
Validation of methylation profiles using NGS
Validations of 450k results were done by deep sequencing 
of bisulfite amplicons using a subset of 28 samples. For 
PCR amplicon design 16 regions were selected (Addi-
tional file  2: Table  S20). The amplicons were designed 
to overlap or be located close to CpGs featured on 450k 
platform. PCRs were set up in 30 µ l reactions using 3 µ l 
of 10× Hot Fire Pol Buffer (Solis BioDyne, Tartu, Esto-
nia), 4  µ l of 10  mM d’NTPs (Fisher Scientific, Pitts-
burgh, USA), 2.25 µ l of 25  mM MgCl2 (Solis BioDyne, 
Tartu, Estonia), 0.6 µ l of amplicon specific forward and 
reverse primer (10 µ M each), 0.3 µ l of Hot FirePol DNA 
Polymerase (5 U/µ l ; Solis Biodyne, Tartu, Estonia), 
1 µ l of bisulfite DNA and 18.25 µ l of double distilled 
water. PCRs were run in an ABI Veriti thermocycler 
(Life Technologies, Karlsbad, USA) using the follow-
ing program: 95 ◦C for 10  min, then 40 cycles of 95 ◦C 
for 1 min, 2.5 min of 56 ◦C and 40 sec at 72 ◦C , followed 
by 7 min of 72 ◦C and hold at 4 ◦C . PCR products were 
cleaned up using Agencourt AMPure XP Beads (Beck-
man Coulter, Brea, USA). All amplified products were 
diluted to 4 nM. Next, sequencing adapters compatible 
to the MiSeq platform (Illumina, San Diego, USA) were 
attached by PCR: a typical 50 µ l reaction contained 25 µ l 
of the DNA pool, 5 µ l of 10× HotStartTaq buffer (Qia-
gen, Hilden, Germany), 4 µ l of 10 mM d’NTPs, 2 µ l of 
25 mM MgCl2 , 2.5 µ l of 10 µ M universal-primer, 2.5 µ l 
of 10 µ M index-primer (unique for each sample), 0.6 µ l 
of HotStartTaq polymerase (Qiagen, Hilden, Germany) 
and 8.6 µ l of double distilled water. The reactions were 
incubated for 15  min at 97  ◦C , followed by 5 cycles of 
97 ◦C (30 s), 60 ◦C (30 s) and 72 ◦C (30 s). After another 
AMPURE bead-based cleanup step, samples were quanti-
fied by a Qubit High Sensitivity Assay (Life Technologies, 
Karlsbad, USA) and diluted to 10 nM. Finally, all samples 
were pooled and loaded on an Illumina MiSeq sequenc-
ing machine. Amplicons were sequenced 2× 250 bp 
(paired end) involving a MiSeq reagent kit V2 chemistry 
(Illumina, San Diego, USA). The raw sequencing data was 
quality checked using FastQ C (v0.10.3) and trimmed for 
adapters and low quality bases using the tools cutad apt 
(v1.3) and Trim Galor e! (v0.3.3). Paired reads were joined 
using the FLASh tool. Next, reads were sorted in a two-
step procedure by (1) the NGS barcode adapters to assign 
Sample ID and (2) the initial 15 bp to assign amplicon ID. 
Subsequently, the sorted data was loaded into the BiQAn 
alyze r HT software 22 using the following settings: the 
analyzed methylation context was set to ‘CG’, minimal 
sequence identity was set to 0.8 and minimal conversion 
rate was set to 0.95. The filtered high quality reads were 
then used for methylation calls of the respective CpGs. 
For non-CpG methylation analysis the methylation con-
text was set to “C” and minimal sequence identity was set 
to 0.7.
Public datasets
Public DNA methylation data from sorted frontal cor-
tex brain samples were downloaded from GEO accession 
GSE41826  [35]. Only data from 29 Caucasian control 
donors were used and merged with our own sorted data. 
Two public brain tissue datasets were downloaded from 
GEO (GSE59685 [82] and GSE80970 [121]) and—in addi-
tion to our own tissue cohort—used for the comparison 
of sorted and bulk brain tissue data. Data from sorted 
prefrontal cortex brain samples (NeuN-positive only) 
under GEO accession GSE98203  [61] were downloaded 
(fully processed methylation values for 28 healthy control 
samples) and used for replication of top aging markers in 
neurons.
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participants were in accordance with the ethical stand-
ards of the institutional and/or national research com-
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